Phase 3 Transverse Myelitis Trial, Recruiting NCT06413654 Sponsor: Shanghai Jiaolian Drug Research and Development Co., Ltd Condition: Transverse Myelitis
Back to Transverse Myelitis

Phase 3 Transverse Myelitis Trial, Recruiting

NCT06413654
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed with NMOSD (Neuromyelitis Optica Spectrum Disorder).
  • You have had at least 1 relapse (flare-up) of NMOSD in the past year, or at least 2 relapses in the past 2 years.
  • If you are a woman who could become pregnant, your pregnancy test must be negative within 7 days before starting the study drug.
  • If you or your partner could become pregnant, you agree to use reliable contraception during the study and for 6 months after finishing the study drug.
  • You are willing to voluntarily take part, have fully understood the study, sign a consent form, and are able to follow and complete all study procedures.

Who may not be able to join:

  • Your NMOSD is considered severe enough that the study doctor feels it would not be safe for you to participate.
  • You have a long-term active immune system disease that requires ongoing treatment.
  • You have received anti-CD20 therapy or other treatments that reduce certain immune cells within the past 6 months.
  • You have received certain specific medications within set time periods before starting the study (confirm with trial site for details).
  • You have taken part in another drug clinical trial within the past 28 days.
  • You have previously received a stem cell transplant or radiation to the lymph nodes.
  • You are currently pregnant, breastfeeding, or plan to have a baby during the trial.
  • You had a major surgery within the 2 months before screening, or are expected to have major surgery during the trial.
  • You have a severe, worsening, or uncontrolled illness that the study doctor believes puts you at higher risk.
  • You have had a gastrointestinal perforation (a hole in your gut) or an abnormal internal channel (fistula) in the past 6 months.
  • You received a live or weakened vaccine in the 4 weeks before starting the study, or plan to receive one during the trial.
  • You currently have, or have had in the past month, a severe or ongoing infection.
  • You have tested positive on a tuberculosis screening blood test (gamma interferon release test).
  • You currently have active hepatitis or have a history of serious liver disease.
  • You have an uncontrolled illness affecting your whole body, or any other reason the study doctor feels makes joining the trial unsuitable.
  • Your laboratory (blood or urine) test results are abnormal (confirm with trial site for specific values).
  • You have had a problem with alcohol or drug misuse in the past 6 months, or are currently misusing alcohol or drugs.
  • You have severe mental health symptoms that make it difficult to cooperate with the study team.
  • You are unable to have MRI (magnetic resonance imaging) scans during the study, or have any other condition the study doctor feels makes participation unsuitable.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 0086-010-59978555

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Shanghai Jiaolian Drug Research and Development Co., Ltd
Registry
ClinicalTrials.gov
Start date
17 July 2024
Est. completion
31 October 2027

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Time to first NMOSD Attack During RCP

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov